AVIR Q1 2022 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$30M

Operating Income

-$42M

Net Income

-$42M

EPS (Diluted)

$-0.50

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$717M

Total Liabilities

$37M

Stockholders' Equity

$680M

Cash & Equivalents

$706M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$66M	-100.0%
Gross Profit	-$30M	$39M	-175.2%
Operating Income	-$42M	$31M	-237.6%
Net Income	-$42M	$31M	-237.0%